Expanding Entresto benefits/maximizing tx for inpatients

Novartis to hold a meeting about expanding Enresto's benefit/indication

"Global guidelines recommends, Entresto as primary tx, applicable in Korea"

Entresto, Novartis' chronic heart failure treatment, has expanded both indications and benefits.

 

Enresto can be used even in patients with more than 40% and less than 60% of the ejection fraction, which has been in great demand.

 

In addition, it is expected that Entresto's position will be further strengthened as hospitalized heart failure patients can use Entresto as a primary drug.

 

Novartis Korea held an online press conference on the 24th to commemorate the expansion of Entresto benefits and indications.

 

Kang Seok-min, a professor of cardiology at Yonsei University's Sinchon Severance Hospital, and Cho Hyun-jae, a professor of circulatory medicine at Seoul National University Hospital, attended to share the meaning of expanding benefits.

 

rom the left, Park Soo-jin, director of the Cardiovascular Metabolism Division of Novartis Korea, Kang Seok-min, professor of cardiology at Yonsei University Sinchon Severance Hospital, and Cho Hyun-jae, professor of circulatory medicine at Seoul National University Hospital

Entresto is the first Angiotensin receptor-Neprilsysin inhibitor (ARNI) treatment in Korea and the only new drug that works directly on the heart.

 

It acts on cardiac nerve hormones in two ways to activate NP nerve hormones that are beneficial to cardiovascular systems, while suppressing RAAS that is harmful to cardiovascular systems.

 

In February, Entresto added an indication of 'reducing the risk of death from cardiovascular disease and hospitalization due to heart failure' in patients with chronic heart failure with lower left ventricular systolic function than normal.

 

Starting this month, for patients who have been hemodynamically stabilized after hospitalization due to acute non-compensatory heart failure, salaries have also been expanded to those without ACE inhibitors or angiotensin II receptor blocking.

 

Entresto can be reimbursed as a primary drug for inpatients.

 

According to Professor Kang Seok-min, 83% of patients with chronic heart failure are hospitalized more than once for acute heart failure, and one in four patients is hospitalized again for 30 days after discharge.

 

Up to 10% die.

 

Effective initial treatment that can reduce re-hospitalization is important.

 

Entresto is recommended as a standard treatment in domestic and foreign heart failure treatment guidelines, but it was difficult to use it initially in Korea as a limited standard.

 

Professor Kang said, "Inpatients have not been able to use Entresto in the first round, but clinical studies have supported the importance of using drugs that can reduce mortality at the time of hospitalization," adding, "Now domestic inpatients are expected to use Entresto to significantly reduce re-entry and mortality." Entresto has also expanded its use in patients with a heart rate of more than 40% to less than normal (about 60%), which has been in unmet demand.

 

Reduced hardness of ejection rate and some conservative patients can be treated with Entresto.

 

Throughout this, Entresto has become the drug with the widest range of chronic heart failure indications in Korea.

 

Entresto showed the greatest clinical effect in patients with a heart rate of 60% or less.

 

Professor Cho Hyun-jae said, "When looking at the left ventricular ejection rate according to the quintile, it showed a consistent positive effect from less than 25% to less than 60%," adding, "9.6% of patients who preserved the ejection rate were progressing heart failure a year later.

 

There have been many studies so far, but Entresto is expected to benefit from proving its effectiveness for the first time." Professor Cho then said, "Recently, SGLT-2 inhibitors have also shown some effects in preserving the ejection rate," adding, "Entresto and SGLT-2 inhibitors play different roles in three axes of heart failure treatment.

 

Therefore, since the two drugs are not in a substitute relationship, but in a complementary relationship, standard treatment will move toward using Entresto and SGLT-2 together in the future, he added.

 

Entresto surpassed 30 billion won in outpatient prescriptions within five years of its launch.

 

Last year, prescriptions amounted to 32.3 billion won, up 37.3% from the previous year.